FTSE 100 news / Companies and sectors / GSK / 21 October 2026
GSK (GSK): news on Wednesday 21 October 2026
+10.0 strongly positive
Coverage was dominated by the FDA approval of Hibsago for chronic hepatitis B and accelerated approval of Jemperli in rectal cancer. The HUTCHMED licence deal closing and a Jefferies Buy rating added support, with only a contract breach hearing involving Tesaro as a minor negative.
What drove it
- Hibsago FDA approval
- Jemperli rectal cancer approval
- HUTCHMED licence deal
The 26 stories
- +10.0 Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)
Company announces US approval of Hibsago - +10.0 US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Reuters reports approval allowing patients to stop treatment - +10.0 FDA approves GSK's ASO as functional cure for hepatitis B
Approval described as functional cure for hepatitis B - +10.0 FDA approves GSK’s Hibsago for chronic hepatitis B treatment By Investing.com
FDA approval of Hibsago for chronic hepatitis B is major positive - +10.0 GSK Says US FDA Approves Hibsago For Chronic Hepatitis B
Same FDA approval of Hibsago, strongly positive - +10.0 GSK wins approval of bepirovirsen for hepatitis B (GSK:NYSE)
Approval of bepirovirsen for hepatitis B - +10.0 FDA approves GSK's Hibsago for sustained control of hepatitis B
FDA approval for hepatitis B drug, positive - +10.0 GSK’s Hibsago approved by FDA for treatment of CHB
FDA approval of Hibsago for chronic hepatitis B - +10.0 FDA Greenlights GSK’s Chronic HBV Antisense Oligo With Roche CDx Test
FDA approval alongside companion diagnostic test - +10.0 GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer
Accelerated FDA approval for Jemperli in rectal cancer - +10.0 GSK's Jemperli wins FDA accelerated approval as first immunotherapy for MSI-H/dMMR locally advanced rectal cancer
First immunotherapy approved for locally advanced rectal cancer - +10.0 GSK’s Jemperli wins accelerated nod in rectal cancer
Jemperli accelerated approval in rectal cancer - +10.0 GSK wins FDA approval for rectal cancer drug
FDA approval for rectal cancer drug - +10.0 GSK's Jemperli Approved in MSI-H/dMMR Rectal Cancer October 20, 2026
Jemperli approved in MSI-H/dMMR rectal cancer - +9.2 GSK (LSE:GSK) Early Jemperli Approval And Hepatitis B Decision Put Pipeline In Focus
Jemperli and hepatitis B decisions put pipeline in focus - +7.5 GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
New drugs and pipeline seen as long-term growth drivers - +7.0 HUTCHMED closes $110M licensing deal with GSK for cancer therapy
Closed $110M licence deal adds cancer pipeline asset - +6.7 HUTCHMED Announces Closing of Exclusive Global License Agreement with GSK for HMPL-A830
Licence agreement closing adds oncology asset - +6.7 HUTCHMED closes exclusive license deal with GSK for KRAS-EGFR antibody therapy outside China.
Exclusive licence closed for antibody therapy outside China - +6.7 Jefferies keeps Buy rating for GSK stock ahead of results - ad-hoc-news.de
Jefferies maintains Buy rating ahead of results - +6.7 HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
Licence closing gives GSK rights outside China - +5.8 Hutchmed's KRAS-EGFR Conjugate Therapy Goes Global as $110 Million Upfront Payment Nears
Licensing deal for KRAS-EGFR therapy extends GSK oncology pipeline - +5.0 FTSE 100 GSK (LSE:GSK) Delivers a Big Dividend This Week
Dividend payout highlighted for shareholders - −4.2 AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach
Contract breach hearing with Tesaro creates legal uncertainty - +0.8 GSK stock: At 17.97 percent below its 52-week high, GSK stock sits - ad-hoc-news.de
Share price sits below 52-week high, factual - +0.3 GSK trades flat as buyer support stabilizes price near key levels
Shares trading flat, neutral
GSK: every day · Pharma and healthcare on 21 October 2026 · FTSE 100 overview for the day